Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.54 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.54 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4317024 | 0.89 | LMNA (0.58) | LMNAMEN1KMT2AALDH1A1HTT | |
| SCHEMBL4321348 | 0.86 | LMNA (0.55) | LMNAMEN1KMT2AALDH1A1HTT | |
| SCHEMBL4424697 | 0.86 | LMNA (0.68) | LMNAMEN1KMT2AALDH1A1HTT | |
| SCHEMBL4429472 | 0.86 | FASN (0.49) | — | |
| SCHEMBL4421894 | 0.85 | ALDH1A1 (0.56) | ALDH1A1KDM4E | |
| SCHEMBL4426358 | 0.85 | ALDH1A1 (0.64) | ALDH1A1 | |
| SCHEMBL4420161 | 0.84 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL4422358 | 0.83 | — | — | |
| SCHEMBL4418456 | 0.82 | NAMPT (0.49) | TLR8TLR7 | |
| SCHEMBL4419055 | 0.82 | SLC6A7 (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | WYETH (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | GRM5, GRIK5, GRM1 | LMNA 4354/4885MEN1 4398/4885KMT2A 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.